CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Immune cell infiltration and inflammatory landscape in primary brain tumours.
我们的数据表明,5-LOX与GzmB的表达在RNA和蛋白质水平上均呈正且显著的相关性。需要进一步评估以理解5-LOX与免疫浸润在胶质瘤进展中的相互作用。
原发性恶性脑肿瘤占所有脑肿瘤的三分之一以上,尽管通过分子研究来识别癌症驱动突变,但由于肿瘤内高度异质性,目前可用的治疗选择仍具有挑战性。此外,免疫抑制和炎症性肿瘤微环境会促进癌症进展。因此,我们对脑膜瘤和胶质肿瘤进行了免疫和炎症特征分析,以阐明免疫浸润在这些癌症类型中的作用。
使用158个脑肿瘤样本的组织微阵列,我们通过免疫组化(IHC)评估了CD3、CD4、CD8、CD20、CD138、颗粒酶B(GzmB)、5-脂氧合酶(5-LOX)、程序性死亡配体1(PD-L1)、O-6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)和转谷氨酰胺酶2(TG2)的表达。IHC结果通过Spearman相关矩阵进行相关性分析。转录表达、相关性及总生存期(OS)分析利用GEPIA2上公开的胶质母细胞瘤(GBM)和低级别胶质瘤(LGG)队列数据集进行评估。
十个标记物中有七个在至少一个评估队列中显示出显著不同的IHC表达,而CD3、CD4和5-LOX在GBM和星形细胞瘤之间差异表达。相关性矩阵分析显示,5-LOX和GzmB表达在脑膜瘤和GBM中均相关,而5-LOX表达在脑膜瘤和星形细胞瘤队列中均与TG2显著正相关。这些发现通过TCGA-GBM和LGG数据集的相关性分析得到证实。mRNA水平分析表明,与对照组织相比,GBM中CD3(CD3D、CD3E)和CD138(SDC1)表达显著增加。在GBM和LGG中,肿瘤样本中CD4和5-LOX(ALOX5)mRNA水平显著高于正常组织。在GBM队列中,GzmB(GZMB)、SDC1和MGMT基因表达预示较差的总生存期(OS)。此外,在LGG队列中,CD3(CD3D、CD3E、CD3G)、CD8(CD8A)、GZMB、CD20(MS4A1)、SDC1、PD-L1、ALOX5和TG2(TGM2)基因表达增加与较差的OS相关。
BACKGROUND: Primary malignant brain tumours are more than one-third of all brain tumours and despite the molecular investigation to identify cancer driver mutations, the current therapeutic options available are challenging due to high intratumour heterogeneity. In addition, an immunosuppressive and inflammatory tumour microenvironment strengthens cancer progression. Therefore, we defined an immune and inflammatory profiling of meningioma and glial tumours to elucidate the role of the immune infiltration in these cancer types. METHODS: Using tissue microarrays of 158 brain tumour samples, we assessed CD3, CD4, CD8, CD20, CD138, Granzyme B (GzmB), 5-Lipoxygenase (5-LOX), Programmed Death-Ligand 1 (PD-L1), O-6-Methylguanine-DNA Methyltransferase (MGMT) and Transglutaminase 2 (TG2) expression by immunohistochemistry (IHC). IHC results were correlated using a Spearman correlation matrix. Transcript expression, correlation, and overall survival (OS) analyses were evaluated using public datasets available on GEPIA2 in Glioblastoma (GBM) and Lower Grade Glioma (LGG) cohorts. RESULTS: Seven out of ten markers showed a significantly different IHC expression in at least one of the evaluated cohorts whereas CD3, CD4 and 5-LOX were differentially expressed between GBMs and astrocytomas. Correlation matrix analysis revealed that 5-LOX and GzmB expression were associated in both meningiomas and GBMs, whereas 5-LOX expression was significantly and positively correlated to TG2 in both meningioma and astrocytoma cohorts. These findings were confirmed with the correlation analysis of TCGA-GBM and LGG datasets. Profiling of mRNA levels indicated a significant increase in CD3 (CD3D, CD3E), and CD138 (SDC1) expression in GBM compared to control tissues. CD4 and 5-LOX (ALOX5) mRNA levels were significantly more expressed in tumour samples than in normal tissues in both GBM and LGG. In GBM cohort, GzmB (GZMB), SDC1 and MGMT gene expression predicted a poor overall survival (OS). Moreover, in LGG cohort, an increased expression of CD3 (CD3D, CD3E, CD3G), CD8 (CD8A), GZMB, CD20 (MS4A1), SDC1, PD-L1, ALOX5, and TG2 (TGM2) genes was associated with worse OS. CONCLUSIONS: Our data have revealed that there is a positive and significant correlation between the expression of 5-LOX and GzmB, both at RNA and protein level. Further evaluation is needed to understand the interplay of 5-LOX and immune infiltration in glioma progression.
MEMBER ACCOUNT
登录成功会直接打开下一页。